Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
|Poll|August 14, 2019
Mini Quiz: Malignant Catatonia
Author(s)Gregory Fricchione, MD
Key Takeaways
- Malignant catatonia requires prompt recognition and intervention to prevent severe complications and improve outcomes.
- Benzodiazepines, especially lorazepam, are the first-line treatment due to their rapid efficacy in symptom relief.
What is the best treatment for malignant catatonia, which is characterized by catatonic symptoms plus fever and hyperautonomia and is associated with significant morbidity and mortality? Take the quiz.
Advertisement
What is the best treatment for malignant catatonia? Scroll down to take the quiz.
For malignant catatonia, which is characterized by catatonic symptoms plus fever and hyperautonomia and is associated with significant morbidity and mortality, the best treatment choice below would be:
Advertisement
Related to this article
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.
An endocrinologist warns psychiatrists against overreading peripheral thyroid hormones and flags kelp and T3 microdosing as underrecognized risks.
Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
Phase 2 Clinical Study Initiated: Evaluating NBI-'567 for the Treatment of Adults With Alzheimer Disease
5